Backed by a pi­o­neer in BiTE tech, Har­poon marks a course for an IPO and an ear­ly dis­play of po­ten­tial

Can a next-gen BiTE de­vised by a pi­o­neer in the field at­tract in­vestors in­to an on­col­o­gy IPO based al­most en­tire­ly on mouse da­ta? Har­poon Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.